Developed through the integration of Inocras's comprehensive CancerVision™ WGS cancer profiling platform and Ultima Genomics' ppmSeq™ technology, MRDVision delivers a breakthrough approach for ...

Shares of Exact Sciences Corp. (EXAS) traded over 2% higher on Tuesday afternoon after the company launched a new test ...

Myriad Genetics, Inc. announced that it will present new clinical data on its Precise MRD test at the upcoming American Association for Cancer Research (AACR) Annual Meeting, focusing on its ...

The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence ...

Moreover, oligometastatic ccRCC poses a unique challenge for MRD assays because tumors tend to be heterogeneous, slow growing, low shedding, and generally limited in trackable mutations1.

Study findings suggested that assessing ctDNA levels was as good or better at predicting recurrence than experimental tests ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive ...

Summary: Myriad's Precise MRD test is an ultrasensitive second-generation hybrid-capture-based tumor-informed assay that ...